<DOC>
	<DOC>NCT01572012</DOC>
	<brief_summary>This is a randomized, open-label Phase 1 pharmacokinetic, tolerability, and safety study of ondansetron and Hylenex given subcutaneously compared to ondansetron given intravenously, intramuscularly, and orally in normal healthy volunteers.</brief_summary>
	<brief_title>Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers</brief_title>
	<detailed_description>This is a randomized, open label, 4 way crossover Phase 1 study of the pharmacokinetics, safety and tolerability of a 4 mg dose of ondansetron administered subcutaneously with Hylenex recombinant compared to 4 mg doses of ondansetron administered intravenously and intramuscularly and an 8 mg dose of ondansetron administered orally.</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>Male or female volunteers 1965 years old Females must be nonlactating and nonpregnant (negative serum pregnancy test at screening)and agree to practice effective birth control for at least 30 days after study completion Nonsmoker or no tobacco/nicotine use in previous 6 months Intact normal skin without obscuring tattoos, pigmentation or lesions Adequate venous access in upper extremities Normal vital signs, ECG, and labs or assessed by the Investigator as NCS Serum hemoglobin within site's normal range Negative drug and alcohol screen Able to make decisions and comply with study requirements History of drug or alcohol abuse or positive drug and alcohol screen Abdominal surgery within the last 30 days Phenylketonuria Tobacco or nicotine use within previous 6 months Hypersensitivity or contraindication to ondansetron or other 5HT3 receptor agonists Received ondansetron within 4 days prior to Day 1 Known allergy to hyaluronidase or other ingredient in Hylenex recombinant Lower extremity edema Creatinine clearance &lt; 60 mL/min Dehydration (Grade 2 or higher) Hypersensitivity or contraindication to heparin Abnormal ECG with clinically significant QT prolongation or history of Female who is pregnant or breastfeeding Participation in a clinical trial (drug or device) within 30 days of enrollment Clinically significant medical history, major systemic disease, intercurrent illness, physical examination finding, or clinical laboratory test result that risks the subject's safety or interfere with interpretation of study results Not able to comply with study requirements</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>tolerability</keyword>
</DOC>